Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Biofrontera (BFRI)
Marpai (MRAI)
Cingulate, Inc. (CING)
Stronghold Digital Mining, Inc. (SDIG)
Enfusion, Inc. (ENFN)
Portillos Inc. (PTLO)
Winc, Inc. (BEV)
The Vita Coco Company, Inc. (COCO)
P10, Inc. (PX)
Ventyx Biosciences, Inc. (VTYX)
Winc, Inc. (WBEV)
Runway Growth Finance Corp (RWAY)
Aris Water Solutions, Inc. (ARIS)
Minerva Surgical, Inc (UTRS)
Xilio Therapeutics, Inc. (XLO)
Informatica Inc. (INFA)
Arteris, Inc. (AIP)
Priced IPO
Mink Therapeutics, Inc. (INKT)
Paragon 28, Inc. (FNA)
Ihs Holding Limited (IHS)
Gitlab Inc. (GTLB)
Lucid Diagnostics, Inc. (LUCD)
Healthcare Triangle (HCTI)
AvidXchange (AVDX)
Cognition Therapeutics, Inc. (CGTX)
Isoplexis Corporation (ISO)
Pyxis Oncology, Inc. (PYXS)
Life Time Group Holdings, Inc. (LTH)
Theseus Pharmaceuticals, Inc. (THRX)
Tricon Residential (TCN)
Volcon (VLCN)
Nuvei (NVEI)
Tdcx, Inc. (TDCX)
First Watch Restaurant Group, Inc. (FWRG)
Exscientia Limited (EXAI)
Warby Parker (WRBY)
Olaplex Holdings Inc. (OLPX)
More companies

HCW Biologics (HCWB)

Sector - Healthcare

Price chart

-66%
Return from IPO

Company News

IPO Profile

About company

Company Logo
They are an innovative clinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. They believe age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. They believe their approach has the potential to provide an innovative treatment of these age-related diseases. Their gateway indication is oncology. By the end of 2021, they expect to have four active clinical trials to evaluate their molecules for cancer indications. There are currently two ongoing Phase 2 clinical trials to evaluate their molecule, HCW9201, in a cell based therapy treatment for generation of ML-NK cell products for patients with relapsed / refractory acute myeloid leukemia (“r/r AML”). They developed the protocol in conjunction with the sponsor, Washington University, and have licensed limited rights for ex vivo use of this molecule to Wugen Inc.
Industry
Pharmaceutical Preparations
CEO CFO
Hing C. Wong Rebecca Byam
Employees Founded
40 2018

Contacts

Address: 2929 N Commerce Parkway Miramar, Fl 33025

Telephone: (954) 842-2024

Web page: http://www.hcwbiologics.com

IPO information

First Trade Date 7/20/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 5.6
Shares Revised (MM) 7
Expected offer amount (MM) $50
Realized offer amount(MM) $56

Financial Data (last reporting year)

Market Cap (MM) $319.45
Revenues (MM) $4.1
Net Income (Loss) (MM) $-6.3

Voting

What do you think will happen with the HCWB share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: EF Hutton

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
EF Hutton
CO-Managers
Revere Securities

Sector: Healthcare

Tweets about $HCWB

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats